Nanoform Finland (OSTO:NANOFS) Total Liabilities : kr125.15 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Nanoform Finland Total Liabilities?

Nanoform Finland's Total Liabilities for the quarter that ended in Dec. 2023 was kr125.15 Mil.

Nanoform Finland's quarterly Total Liabilities declined from Jun. 2023 (kr143.93 Mil) to Sep. 2023 (kr128.62 Mil) and declined from Sep. 2023 (kr128.62 Mil) to Dec. 2023 (kr125.15 Mil).

Nanoform Finland's annual Total Liabilities declined from Dec. 2021 (kr152.61 Mil) to Dec. 2022 (kr147.63 Mil) and declined from Dec. 2022 (kr147.63 Mil) to Dec. 2023 (kr125.15 Mil).

Nanoform Finland Total Liabilities Historical Data

The historical data trend for Nanoform Finland's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanoform Finland Total Liabilities Chart

Nanoform Finland Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

52.17

114.47

152.61

147.63

125.15

Nanoform Finland Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															147.63	157.62	143.93	128.62	125.15

Nanoform Finland Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Nanoform Finland's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	66.948	+	(58.201	+	7.105427357601E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	125.15

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	874.021	-	748.872
	=	125.15

Nanoform Finland's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	66.948	+	(58.201	+	7.105427357601E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	125.15

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	874.021	-	748.872
	=	125.15

Nanoform Finland Total Liabilities Related Terms

Thank you for viewing the detailed overview of Nanoform Finland's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanoform Finland (OSTO:NANOFS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoform Finland PLC (OSTO:NANOFS) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

NANOFH:Finland 4YL:Germany

Address

Cultivator II, Viikinkaari 4, Helsinki, FIN, 00790

Website

https://www.nanoform.com

Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications.

Nanoform Finland (OSTO:NANOFS) Headlines

No Headlines